Document Detail

Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity.
MedLine Citation:
PMID:  18927337     Owner:  NLM     Status:  MEDLINE    
Preparation with recombinant human thyroid-stimulating hormone (rhTSH) for thyroid remnant ablation results in lower extrathyroidal radiation than does hypothyroidism. The objective of this prospective study was to compare the damage caused by 131I (3.7 GBq) when these 2 preparations are used. METHODS: Ninety-four consecutive patients who underwent total thyroidectomy and remnant ablation with 3.7 GBq of 131I were studied. Thirty patients (group A) received rhTSH, and 64 (group B) were prepared by levothyroxine withdrawal. Damage to salivary glands, ovaries, and testes; hematologic damage; and oxidative injury were evaluated by measurement of serum amylase, follicle-stimulating hormone (FSH), complete blood count, and plasma 8-epi-PGF2alpha before and after radioiodine. The 2 groups were similar in sex, age, and the results of baseline assessment. RESULTS: The rate of successful ablation (stimulated thyroglobulin level < 1 ng/mL and negative findings on neck ultrasonography) was 90% in group A and 80% in group B. Considering only patients with a preablation thyroglobulin level greater than 1 ng/mL, these rates were 80% and 70.6%, respectively. Only 1 patient (3.3%) reported transient headaches with rhTSH. Elevated FSH levels after therapy were observed in 4 of 9 (44%) men in group A versus 16 of 18 (89%) in group B (P < 0.03), with a mean increase of 105% versus 236% (P < 0.001), respectively. In women, elevated FSH was observed in 1 of 13 (7.7%) patients in group A versus 6 of 30 (20%) in group B (P = 0.4), with a mean increase of 65% versus 125% (P < 0.001). Thrombocytopenia or neutropenia occurred in 2 of 28 (7%) patients in group A versus 12 of 56 (21.4%) in group B (P = 0.1), with a mean decrease of 20% versus 45% and 25% versus 52% (P < 0.01) for neutrophils and platelets, respectively. Hyperamylasemia and symptoms of acute sialoadenitis occurred in 11 of 30 (36.6%) versus 48 of 60 (80%) (P < 0.001) and in 9 of 30 (30%) versus 35 of 60 (58.3%) (P = 0.01), respectively. 8-Epi-PGF2alpha was found to be elevated after 131I in 14 of 25 (56%) patients in group A versus 45 of 45 (100%) in group B (P < 0.001), with a mean increase of 60% versus 125% (P < 0.001). CONCLUSION: The lower radiotoxicity with rhTSH, suggested in dosimetry studies, was confirmed in the present prospective investigation, and this advantage occurred without compromising the efficacy of treatment.
Pedro Weslley Rosário; Michelle Aparecida Ribeiro Borges; Saulo Purisch
Related Documents :
24473667 - Three-dimensional computed tomography analysis of variations in the middle hepatic vein...
23140947 - The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lac...
9534037 - Treatment of hyperthyroidism with radioactive iodine.
9420337 - Relation between therapy for hyperthyroidism and the course of graves' ophthalmopathy.
17126477 - The detour extra-anatomic stent--a permanent solution for benign and malignant ureteric...
16542207 - Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a...
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2008-10-16
Journal Detail:
Title:  Journal of nuclear medicine : official publication, Society of Nuclear Medicine     Volume:  49     ISSN:  0161-5505     ISO Abbreviation:  J. Nucl. Med.     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-11-05     Completed Date:  2008-12-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0217410     Medline TA:  J Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1776-82     Citation Subset:  IM    
Department of Thyroid, Endocrinology Service, Santa Casa de Belo Horizonte, Belo Horizonte, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Ablation Techniques / methods*
Follow-Up Studies
Iodine Radioisotopes / adverse effects,  therapeutic use
Middle Aged
Recombinant Proteins / therapeutic use*
Thyroid Gland / radiation effects*,  surgery*
Thyrotropin / therapeutic use*
Thyroxine / therapeutic use
Treatment Outcome
Young Adult
Reg. No./Substance:
0/Iodine Radioisotopes; 0/Recombinant Proteins; 7488-70-2/Thyroxine; 9002-71-5/Thyrotropin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quantitative analysis of NK1 receptor in the human brain using PET with 18F-FE-SPA-RQ.
Next Document:  Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET im...